Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30429736 | 0.88 | CYP2A6 (0.37) | — | |
| SCHEMBL25569710 | 0.88 | CYP2A6 (0.37) | — | |
| SCHEMBL25572162 | 0.85 | — | — | |
| SCHEMBL25572155 | 0.84 | CHRNA7 (0.32) | CHRNA7HTR3ACYP3A4CYP2D6 | |
| SCHEMBL25569728 | 0.84 | HSP90AB1 (0.30) | — | |
| SCHEMBL25670665 | 0.81 | CYP3A4 (0.46) | CHRNA7HTR3ACYP3A4CYP2D6SLC6A2 | |
| SCHEMBL25569721 | 0.81 | CHRNA7 (0.30) | CHRNA7HTR3ACYP3A4CYP2D6SLC6A2 | |
| SCHEMBL25572159 | 0.81 | CYP2D6 (0.32) | CHRNA7HTR3ACYP3A4CYP2D6SLC6A2 | |
| SCHEMBL25569726 | 0.81 | CYP3A4 (0.31) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25572166 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | SLC6A3, CREBBP, SLC1A2 | CHRNA7 408/4885HTR3A 402/4885CYP3A4 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.